Next Article in Journal
In Vivo Skin Hydrating Efficacy of Fish Collagen from Greenland Halibut as a High-Value Active Ingredient for Cosmetic Applications
Next Article in Special Issue
Pyrrole-Containing Alkaloids from a Marine-Derived Actinobacterium Streptomyces zhaozhouensis and Their Antimicrobial and Cytotoxic Activities
Previous Article in Journal
Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis
Previous Article in Special Issue
Antibacterial Mechanism of Chitosan–Gentamicin and Its Effect on the Intestinal Flora of Litopenaeus vannamei Infected with Vibrio parahaemolyticus
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Survey of Didemnin Depsipeptide Production in Tistrella

1
Terra Bioworks Inc., Middleton, WI 53562, USA
2
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 9500 Gilman Drive, San Diego, CA 92093-0657, USA
3
Department of Chemistry and Biochemistry, University of California, San Diego, CA 92093-0358, USA
4
Xenobe Research Institute, P.O. Box 3052, San Diego, CA 92163-1052, USA
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2023, 21(2), 56; https://doi.org/10.3390/md21020056
Submission received: 6 December 2022 / Revised: 7 January 2023 / Accepted: 12 January 2023 / Published: 17 January 2023
(This article belongs to the Special Issue Antimicrobial and Antiviral Agents from Marine Sources)

Abstract

:
As one of the first families of marine natural products to undergo clinical trials, the didemnin depsipeptides have played a significant role in inspiring the discovery of marine drugs. Originally developed as anticancer therapeutics, the recent re-evaluation of these compounds including synthetically derived dehydrodidemnin B or Aplidine, has led to their advancement towards antiviral applications. While conventionally associated with production in colonial tunicates of the family Didemnidae, recent studies have identified their biosynthetic gene clusters from the marine–derived bacteria Tistrella mobilis. While these studies confirm the production of didemnin X/Y, the low titer and general lack of understanding of their biosynthesis in Tistrella currently prevents the development of effective microbial or synthetic biological approaches for their production. To this end, we conducted a survey of known species of Tistrella and report on their ability to produce the didemnin depsipeptides. These data were used to develop conditions to produce didemnin B at titers over 15 mg/L.

Graphical Abstract

1. Introduction

First reported in 1981 [1], the didemnin depsipeptides, including the tamandarins [2], represent a unique family of non-ribosomal-produced peptides comprising two or three ester-linked peptides and/or lipids (Figure 1). Among this family, didemnin B and M have demonstrated potent in vitro cytotoxicity [3,4] and in vivo antitumor activity [5] resulting in its translation into clinical trials [6,7,8] against adenocarcinoma of the kidney, advanced epithelial ovarian cancer, and metastatic breast cancer. While initially unexplored, early screening efforts also identified potent antiviral activity against DNA/RNA viruses [9]. Recently, dehydrodidemnin B (Aplidine, Plitidepsin) [7] was shown to have potent activity against the severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) in vitro, in animal models [10,11,12] and in humans [13].
In 2011, a group at the Yakult Central Institute reported the identification of didemnin B from a marine-derived Tistrella mobilis strain [14]. The genus Tistrella was first identified from waste water in Thailand and reported by Shi et al. in 2002 [15], with a second species, T. bauzanensis, identified in 2011 by Zhang et al. from soil in a heavy-metal-contaminated site in Italy [16]. Thus, until the report by Tsukimoto et al. [14], the only record of this genus came from terrestrial sources, albeit aqueous. A year later, a group from Hong Kong working closely with a team at Scripps Institution of Oceanography and University of California, San Diego, published the complete biosynthetic pathway to didemnin X/Y from a free-living Tistrella mobilis strain isolated from the Red Sea [17]. In addition to this pathway, they also used MALDI-imaging to demonstrate in real-time the production of didemnin X/Y as the microbe was growing. Thus, there was absolutely no question that this free-living microbe produced the didemnin depsipeptides.
Figure 1. Structures of select didemnin depsipeptides including aplidine and didemnin B, M, X and Y. Structures are provided with their biosynthetic adenylation (A) domain and amino acid selectivity [17]. The numbers within the hexagons indicate the positions of each ester linkage.
Figure 1. Structures of select didemnin depsipeptides including aplidine and didemnin B, M, X and Y. Structures are provided with their biosynthetic adenylation (A) domain and amino acid selectivity [17]. The numbers within the hexagons indicate the positions of each ester linkage.
Marinedrugs 21 00056 g001
While this compound class has been known to possess potent antiviral activity, only its anti-leukemic activity has been explored clinically until recently [6,7,8,10]. Unfortunately, limited availability of these natural products (currently obtained by isolation from marine tunicates or through total synthesis) has hindered their study and clinical exploration. Recent studies suggest that microbial production of the didemnins from two cultures of their native Tistrella sp. producers yields predominantly uncoupled partial products with low levels (<1 mg/L) of the desired didemnins [14,17]. This evidence not only suggests that microbial culturing presents even further challenges, but also indicates that without the development of heterologous production systems these natural products and their derivatives will remain cost-ineffective for the treatment of viral infections such as SARS-CoV-2 [10,11,12,13].
Although the discovery of a microbial origin for the didemnin depsipeptides suggests a viable means of natural or synthetic biological production, ameliorating the lack of understanding of the biosynthetic potential of Tistrella is critical to its ultimate success. Since the first description in 2002 [15], only a handful of studies have explored the biosynthetic potential of Tistrella; these include recent efforts to evaluate the biosynthetic gene clusters (BGCs) associated with 3–thia–α–amino acid [18], thalassospiramide [19,20], and the didemnin depsipeptides [17]. Here, we apply an algorithm-based approach to evaluate the metabolomic profile of cultures from three strains of Tistrella.

2. Results

2.1. Establishing Viable Culture Conditions

Tistrella are alphaproteobacteria belonging to the Rhodospirillaceae family [15]. Three strains of Tistrella were examined in this study: Tistrella mobilis JCM21370 [15], Tistrella bauzanensis BZ78 (DSM22817) [16], and Tistrella mobilis YIT12409 [14]. We began by identifying media and conditions to culture them. We found that T. mobilis JCM21370, T. mobilis YIT12409, and T. bauzanensis DSM22817 all grew readily on 74NA Petri dishes at 30 °C for the mobilis strains and 25 °C for the bauzanensis strain. In order to test antibiotic resistance in T. mobilis JCM21370 and T. mobilis YIT12409, we picked single colonies to 14 mL round-bottom polystyrene tubes containing 3 mL 74NB. After 3 days at 30 °C with 200 RPM shaking, 1 µL was transferred to culture tubes containing fresh 3 mL 74NB and each of the following antibiotics (Table 1): apramycin (50 µg/mL), carbenicillin (50 µg/mL), chloramphenicol (25 µg/mL), colistin (5 µg/mL), kanamycin (50 µg/mL), hygromycin (100 µg/mL), and nalidixic acid (30 µg/mL). After 3 days at 30 °C with 200 RPM shaking, we compared the growth relative to cultures without any added antibiotic. T. mobilis JCM21370 was resistant to carbenicillin and colistin with no apparent growth defect, while some resistance to nalidixic acid was observed with very weak growth. T. mobilis YIT12409 was only resistant to carbenicillin.

2.2. Comparative Analyses for the Production of Didemnin Depsipeptides

Strains were cultured uniformly for didemnin expression to produce the samples given in Table 2 in the following way: From a frozen (−80 °C) glycerol stock of each strain, we streaked to 74NA Petri dishes and incubated at either 25 °C (T. bauzanensis) or 30 °C (T. mobilis) until well-formed colonies appeared. For 100 mL- to 200 mL-scale cultures, a single colony was picked to 250 mL glass conical flasks containing 100 mL of media and incubated with 200 RPM shaking according to the conditions given in Table 2. For 1 L to 5 L cultures (used to test scaled up isolation), a single colony was picked to 100 mL of 74NB, incubated with 200 RPM shaking at either 20 °C for 5 days (T. bauzanensis) or 30 °C for 3 days (T. mobilis). Then, 1 mL was transferred to 2 L glass conical flasks containing 1 L of media and incubated with 200 RPM shaking according to the conditions given in Table 2. Cultures developed from this study were extracted and evaluated using NMR (Section 2.3) and atomic sort methods (Section 2.3).

2.3. NMR Data Collection

Aliquots (5–10% of total sample) from each crude extract (see Materials and Methods for preparation in Section 2.2) were dried by N2 flow and dissolved in 200 µL of CD3OD. A 50 µL aliquot of this sample was added to a 1.7 mm NMR SampleJet (Bruker) NMR tube. NMR data were acquired with a Bruker Avance III 600 MHz spectrometer equipped with a 1.7 mm cryoprobe. Chemical shifts were referenced using the corresponding solvent signals (δH 3.31 and δC 49.0 for CD3OD). The NMR spectra were processed using MestReNova 12.0.3 (Mestrelab Research) or TopSpin 3.6 (Bruker Biospin) software.

2.4. Atomic Sort Metabolomics Analysis

Comparison of a database of 1H–13C HSQC-peak lists against a peak list of each Tistrella extract allowed for identification of the components of each culture. The peaks of each compound in the database were matched to the closest peak in each culture spectrum using the Atomic Sort algorithm [21]. This algorithm calculates the Euclidean distance from a query peak to the closest peak in a reference set. The 1H and 13C dimensions are normalized by dividing by the range of chemical shifts for each dimension in the reference set, thus expressing the distance between two peaks as a fraction of the total chemical shift space. Calculating Atomic Sort distances (dAS) between query and reference peak lists, then taking the median d A S ˜ gives a quantitative measure of how well the spectra match. Repeating this for thousands of compounds, then sorting on d A S ˜ enables automated and objective compound identification. Matches to a subset of a reference compound’s peaks indicates the presence of a compound similar, but not identical, to one in the reference set.
Didemnin B (1) was detected in cultures of both T. mobilis strains (Figure 2 and Figure 3, Table 3 and Table 4, and additional spectral data within the Supplementary Information). The T. bauzanensis DSM2281 strain did not produce detectable amounts of the depsipeptide. All three strains produced indole and short peptides, including cyclo(Pro–Tyr) (3, Figure 2), LPIPI (Leu–Pro–Ile–Pro–Ile, 2), and a peptide that was not conclusively identified but is closely related to cyclo(Ile-Pro-Leu-Pro). Additionally, the solvent used for the NMR analysis (CD3OD) and n–hexane, or a long alkyl chain compound—a common impurity—was detected. Table 3 shows the d A S ˜ and the fraction of matched peaks for the identified metabolites. A smaller d A S ˜ indicates a better match and more confidence that the metabolite is present. Values of less than 0.1 indicate the presence of the compound, values of 0.1 to 0.2 suggest a related compound, and higher values are non-specific matches. Of the 200–250 peaks in each extract’s 1H–13C HSQC spectrum, ~50% could be assigned (Figure 3). Full Atomic Sort analyses of T. mobilis JCM21370, T. mobilis YIT12409 and T. bauzanensis DSM22817 are provided in the Supplementary Information.
The amount of each metabolite produced was quantified using integrals from the 1D 1H spectra and the residual CD3OD methyl resonance as an internal standard. The 1H–13C HSQC spectra were used to identify peaks for each metabolite with minimal overlap in the 1H spectra. Table 4 lists concentrations and masses of the metabolites identified in the extracts.

2.5. Didemnin BGC Architecture Analysis

Whole-genome sequence analysis was used to elucidate the presence and architecture of the putative didemnin BGCs in each of the four T. mobilis strains. The pathways from T. mobilis JCM21370 and T. mobilis YIT12409 contained didA–didJ (Figure 4) as elucidated in T. mobilis KA081020–065 [17]. Not surprisingly, the non-didemnin-producing T. bauzanensis DSM22817 strain was missing didC–didH and therefore lacked the machinery to install all but the Pro–Tyr motif, which could be attributed to the production of cyclo(Pro–Tyr) (3). While intact, profound differences were observed between each pathway where the BGC in T. mobilis JCM21370 contained didC–didD and didH–didI as a fusion within a single gene, as compared to T. mobilis KA081020–065. While an active didemnin producer, the GC-rich BGC from T. mobilis YIT12409 is being resequenced to confirm the organization of this GC rich cluster.

3. Discussion

In a detailed metabolomic analysis of extracts, we observed the production of didemnin B (1) by both T. mobilis strains, but not T. bauzanensis (Xu [17] observed didemnin B from T. bauzanensis TIO7329). NMR estimations indicate that these cultures contained ~30 mg/L of 1. In practice, we were able to isolate 15.9 mg of pure didemnin B (1) (see NMR spectral data set in the Supplementary Information), providing an isolated yield of 7.9 mg/L. In prior studies [14,17], the low yield of didemnins was complicated by the fact that the crude extracts contained chemical shifts comparable to that of didemnin B, with the exception of the two ester protons between 4.9 and 5.5 ppm. In our studies, we only observed didemnin B (1), and the formation of other didemnin analogues such as didemnin X/Y was not detected. This simplifies compound purification and allows access to a single didemnin depsipeptide, 1. Such observations further support the theory [17] that additional esterification in didemnin X/Y is transitory, likely as didemnin B is catabolized (or hydrolyzed) upon extended culturing.
This production was then screened across the two T. mobilis strains JCM21370 and YIT12409 using three different media. As shown in Table 5, 1 was produced by both strains in all three media evaluated. The highest titers were obtained from cultures of T. mobilis JCM21370 in 74NB media (K and M, Table 5), with titers predicted as high as 111.7 mg/L (M, Table 5). While not described in depth, the key to providing reproducible yields of 1 arose from careful regulation of the temperature and shaking, as well as conducting the growth in a relatively short period (3 days).
Meticulous isolation efforts enabled the other primary materials within extracts of culture H to be identified (Table 2). We were able to isolate sufficiently pure samples to identify two of the compounds as cyclo(Pro–Tyr) (3) and cyclo(Pro–Phe) (4) as validated by HRMS–ESI–MS for 3 with m/z calcd. for C14H17N2O3 [M+H]+ of 261.1234 and 261.1237 found and 4 with HRMS–ESI–MS with m/z calcd. for C14H17N2O2 [M+H]+ of 245.1285 and 244.1287 found. We also isolated samples of 2 (1H NMR spectrum in Figure 2), which was tentatively assigned as Leu-Pro-Ile-Pro-Ile. Fragments of didemnin B (1) were not detected, and the isoleucine containing peptides were distinguished from isostatine.

4. Materials and Methods

4.1. Strains

Tistrella mobilis JCM21370 was acquired from the Japan Collection of Microorganisms, RIKEN BioResource Center. Tistrella mobilis YIT12409 was received as a gift from Moriya Tsukimoto (Yakult Central Institute). Tistrella bauzanensis DSM22817 was acquired from the DSMZ—German Collection of Microorganisms and Cell Cultures.

4.2. Culture Conditions

T. mobilis JCM21370 and T. mobilis YIT12409 were streaked to 74 Nutrient Agar (74NA; peptone 5 g/L, beef extract 3 g/L, agar 15 g/L) and incubated for 2–3 days at 30 °C until colonies appeared. For liquid cultures, a single colony was picked to 74 Nutrient Broth (74NB) and incubated for 3 days at 30 °C with 200 RPM shaking. T. bauzanensis DSM22817 was streaked to 74NA and incubated for 3–5 days at 25 °C. For liquid cultures, a single colony was picked to 74NB and incubated for 5 days at 20 °C with 200 RPM shaking. Additional samples were obtained by culturing the strains in the following broths: Tryptic Soy Broth (TSB, Research Products International), GYP (glucose 10 g/L, yeast extract 4 g/L, peptone 2 g/L, Instant Ocean 17 g/L), and Seawater-Based Medium [14] (SBM; galactose 1 g/L, gelatin peptone 1 g/L, glycerol 1 g/L, yeast extract 1.5 g/L, peptone 5 g/L, Instant Ocean 30 g/L).

4.3. Extraction

Cultures were frozen and thawed prior to extraction. A common method was used for all extractions. As an example, frozen culture broth from T. mobilis JCM21370 (1 L) grown in 74NB for 3 days at 37 °C with shaking at 200 RPM was warmed to 23 °C, saturated with NaCl and added to a 2 L Squibb separatory funnel (2 L). The mixture was extracted with EtOAc (3 × 1 L), washed with brine (500 mL), and dried on Na2SO4. The solvent was removed by rotary evaporation using a round bottom flask (5 L). The contents of the flask were transferred to a 20 mL scintillation vial (VWR) by sequential washing of the flask with 3:1 EtOAc/MeOH and the solvent removed by rotary evaporation. Samples were stored at −20 °C. An aliquot (1–3%, weighed after transfer for each sample) was removed from each sample, dried in a ½ dram V1235CTFE TFE-lined vial (Glass Vials Inc., Hanover, MD, USA) and dried using N2 flow for NMR analyses as described in Section 4.4.

4.4. NMR Analyses

Aliquots from each extract in Section 4.3 dried by N2 flow were dissolved in 200 µL of CD3OD, and 50 µL of this sample was added to a 1.7 mm NMR SampleJet (Bruker) NMR tube. NMR data were acquired with a Bruker Avance III 600 MHz spectrometer equipped with a 1.7 mm cryoprobe. HSQC spectra were acquired using the Bruker pulse sequence “hsqcedetgpsisp2.3” modified to include a DIPSI-2 spinlock in the relaxation delay for the ASAP protocol [22]. Chemical shifts were referenced using the corresponding solvent signals (δH 3.31 and δC 49.0 for CD3OD). The NMR spectra were processed using Mnova 12.0.3 (Mestrelab Research) or TopSpin 3.6 (Bruker Biospin).

4.5. Purification of Didemnin B

A two-step procedure was used to purify didemnin B (1) from extract H (Table 2), which included fractionation followed by subsequent purification. The entire crude extract (524.2 mg) was dissolved in 5 mL of 9:1 CH2Cl2/MeOH and applied to a 20 cm × 2.5 cm flash column charged with SiliaFlash Irregular Silica Gel P60—40–63 µm mesh, grade 60 (SiliaCycle)—loaded and washed with hexanes. Fractions were collected by the sequential passage of 500 mL of hexanes (fraction A), 2:1 hexanes/EtOAc (fraction B), 1:1 hexanes/EtOAc (fraction C), EtOAc (fraction D), 4:1 EtOAc/MeOH (fraction E), 2:1 EtOAc/MeOH (fraction F), 1:1 EtOAc/MeOH (fraction G), and MeOH (fraction H). A 10 mL aliquot was taken from each fraction, dried with N2 flow and subjected to NMR analysis. Fraction D (42.5 mg) contained 1. All fractions were saved by solvent removal using rotary evaporation followed by transfer to a 20 mL vial (Qorpak) by sequential washing of the flask with 3:1 EtOAc/MeOH and drying the solvent using rotary evaporation. Fraction D was then subjected to a second purification using high quality SiliaFlash 25 µm spherical Silica Gel with a gradient of hexanes to 1:9 hexanes/acetone providing 22.8 mg of 1 (~85% purity), which upon repetition (third purification) provided 15.9 mg of 1 (purity ≥ 98%).

4.6. Genome Sequencing

Single colonies of T. mobilis JCM21370 were picked and cultured in 100 mL 74NB for 3 days at 30 °C with 200 RPM shaking. The cultures were centrifuged at 5000× g for 15 min. The supernatants were discarded and the pellets frozen at –80 °C. The pellets were shipped with dry ice to the Microbial Genome Sequencing Center (Pittsburgh, PA, USA) for gDNA extraction and sequencing. The gDNA samples were sequenced with a combination of Illumina and Oxford Nanopore methods. Quality control and adapter trimming were performed with bcl2fastq [23] and porechop [24] for Illumina and ONT sequencing, respectively. Hybrid assembly with Illumina and ONT reads was performed with Unicycler [25]. The genome sequences for T. bauzanensis DSM22817 and T. mobilis KA081020–065 are available at NCBI with respective accession numbers NZ BMDZ01000001.1 and CP003236.1.

5. Conclusions

We have developed methods to culture didemnin B (1) at >100 mg/L NMR estimated (16 mg/L isolated) levels through a combination of media and growth optimization efforts. These studies indicate that one can direct didemnin production to only afford compound 1, and to do so in a manner that provides effective chromatographic purification (see NMR data on samples of 1 in CD3OD in the Supplementary Information and as tabulated in Table 6). Using 1.7 mm microscaled Atomic Sort [21] analyses, we were able to identify and validate compound purification of small samples (50 µL of extract derived from ~10 mL of culture required) and then translate this into L-scale production. As summarized in Table 5, we observed the production of 1 in cultures of T. mobilis JCM21370 and T. mobilis YIT12409. While not yet fully optimized, the fact that reproducible conditions were identified with significant titer and isolated yields provides a critical next step to meet the supply demands for 1 and associated one-step oxidation to Aplidine (Plitidepsin).
As part of an ongoing study, we identified biosynthetic gene clusters (BGCs) from the three strains evaluated in this program (Figure 4). In spite of the fact that T. bauzanensis TIO7329 was described as producing didemnin [17], analysis of T. bauzanensis DSM22817 showed that this was not the case for this strain. Genomic analysis of T. bauzanensis DSM22817 revealed the putative didemnin BGC was precisely missing genes for didC–didH and therefore lacks the enzymes to install all but the Gln–Gln–Pyr (efforts were not made to isolate or identify this shunt fragment in extracts of T. bauzanensis DSM22817) and Pro–Tyr motifs, which could explain the shunted production of cyclo(Pro–Tyr) (3). This suggests that didABIJ or didAB could be used to insert alternative but compatible modules that would generate new chemistry possibilities. The pathways from T. mobilis JCM21370 contained didA–didJ, as elucidated in T. mobilis KA081020–065 [17]. Efforts are now underway to further explore the genomes of Tistrella including T. mobilis YIT12409 to guide culture optimization and synthetic biological production, with whole-genome sequence and annotation data to be provided subsequently.

Supplementary Materials

The following information can be downloaded at: https://www.mdpi.com/article/10.3390/md21020056/s1. Copies of NMR data and Atomic Sort results.

Author Contributions

Conceptualization, J.J.L.C. and D.A.M.; atomic sort methodology, B.M.D. and J.J.L.C.; strain cultivation, R.J.S. and D.J.; metabolite production, R.J.S.; extraction, J.J.L.C.; NMR analyses, B.M.D. and J.J.L.C.; atomic sort analyses, B.M.D. and J.J.L.C.; didemnin B purification, J.J.L.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded internally at the Xenobe Research Institute and Terra Bioworks.

Data Availability Statement

Copies of raw NMR spectra can be provided by email request to J.J.L.C. at [email protected] or [email protected].

Acknowledgments

We dedicate this manuscript to Madeleine M. Joullié (University of Pennsylvania), whose pioneering work enabled the preparation and medicinal chemical evaluation of the didemnin depsipeptides and played a fundamental role in its early clinical translation. We also thank Kenan Bozhüyük (Max Planck Instiute for Terrestrial Biology) for a detailed review of the genomic data and associated BGC presented herein.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rinehart, K.L., Jr.; Gloer, J.B.; Hughes, R.G., Jr.; Renis, H.E.; McGovren, J.P.; Swynenberg, E.B.; Stringfellow, D.A.; Kuentzel, S.L.; Li, L.H. Didemnins: Antiviral and antitumor depsipeptides from a caribbean tunicate. Science 1981, 212, 933–935. [Google Scholar] [CrossRef] [PubMed]
  2. Vervoort, H.; Fenical, W.; Epifanio, R.D.A. Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae. J. Org. Chem. 2000, 65, 782–792. [Google Scholar] [CrossRef] [PubMed]
  3. Lee, J.; Currano, J.N.; Carroll, P.J.; Joullié, M.M. Didemnins, tamandarins and related natural products. Nat. Prod. Rep. 2012, 29, 404–424. [Google Scholar] [CrossRef] [PubMed]
  4. Vera, M.D.; Joullié, M.M. Natural products as probes of cell biology: 20 years of didemnin research. Med. Res. Rev. 2002, 22, 102–145. [Google Scholar] [CrossRef] [PubMed]
  5. Le Tourneau, C.; Raymond, E.; Faivre, S. Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison. Curr. Pharm. Des. 2007, 13, 3427–3439. [Google Scholar] [CrossRef]
  6. Leisch, M.; Egle, A.; Greil, R. Plitidepsin: A potential new treatment for relapsed/refractory multiple myeloma. Future Oncol. 2019, 15, 109–120. [Google Scholar] [CrossRef]
  7. Alonso-Álvarez, S.; Pardal, E.; Sánchez-Nieto, D.; Navarro, M.; Caballero, M.D.; Mateos, M.V.; Martin, A. Plitidepsin: Design, development, and potential place in therapy. Drug Des. Dev. Ther. 2017, 11, 253–264. [Google Scholar] [CrossRef] [Green Version]
  8. Chun, H.G.; Davies, B.; Hoth, D.; Suffness, M.; Plowman, J.; Flora, K.; Grieshaber, C.; Leyland–Jones, B. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent. Investig. New Drugs. 1986, 4, 279–284. [Google Scholar] [CrossRef]
  9. Weed, S.D.; Stringfellow, D.A. Didemnins A and B. Effectiveness against cutaneous herpes simplex virus in mice. Antivir. Res. 1983, 3, 269–274. [Google Scholar] [CrossRef]
  10. Rodon, J.; Muñoz–Basagoiti, J.; Perez–Zsolt, D.; Noguera–Julian, M.; Paredes, R.; Mateu, L.; Quiñones, C.; Perez, C.; Erkizia, I.; Blanco, I.; et al. Identification of Plitidepsin as Potent Inhibitor of SARS–CoV–2–Induced Cytopathic Effect After a Drug Repurposing Screen. Front. Pharmacol. 2021, 12, 646676. [Google Scholar] [CrossRef]
  11. Sachse, M.; Tenorio, R.; Fernández de Castro, I.; Muñoz–Basagoiti, J.; Perez–Zsolt, D.; Raïch–Regué, D.; Rodon, J.; Losada, A.; Avilés, P.; Cuevas, C.; et al. Unraveling the antiviral activity of plitidepsin against SARS–CoV–2 by subcellular and morphological analysis. Antiviral. Res. 2022, 200, 105270. [Google Scholar] [CrossRef] [PubMed]
  12. White, K.M.; Rosales, R.; Yildiz, S.; Kehrer, T.; Miorin, L.; Moreno, E.; Jangra, S.; Uccellini, M.B.; Rathnasinghe, R.; Coughlan, L.; et al. Plitidepsin has potent preclinical efficacy against SARS–CoV–2 by targeting the host protein eEF1A. Science 2021, 371, 926–931. [Google Scholar] [CrossRef] [PubMed]
  13. Varona, J.F.; Landete, P.; Lopez–Martin, J.A.; Estrada, V.; Paredes, R.; Guisado–Vasco, P.; Fernandez de Orueta, L.; Torralba, M.; Fortun, J.; Vates, R.; et al. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID–19. Life Sci. Alliance 2022, 5, e202101200. [Google Scholar] [CrossRef] [PubMed]
  14. Tsukimoto, M.; Nagaoka, M.; Shishido, Y.; Fujimoto, J.; Nishisaka, F.; Matsumoto, S.; Harunari, E.; Imada, C.; Matsuzaki, T. Bacterial Production of the Tunicate-Derived Antitumor Cyclic Depsipeptide Didemnin B. J. Nat. Prod. 2011, 74, 2329–2331. [Google Scholar] [CrossRef] [PubMed]
  15. Shi, B.H.; Arunpairojana, V.; Palakawong, S.; Yokota, A. Tistrella mobilis gen. nov., sp. nov., a novel polyhydroxyalkanoate–producing bacterium belonging to alpha–Proteobacteria. J. Gen. Appl. Microbiol. 2002, 48, 335–343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Zhang, D.-C.; Liu, H.-C.; Zhou, Y.-G.; Schinner, F.; Margesin, R. Tistrella bauzanensis sp. nov., isolated from soil. Int. J. Syst. Evol. Microbiol. 2011, 61, 2227–2230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Xu, Y.; Kersten, R.D.; Nam, S.-J.; Lu, L.; Al-Suwailem, A.M.; Zheng, H.; Fenical, W.; Dorrestein, P.C.; Moore, B.S.; Qian, P.-Y. Bacterial Biosynthesis and Maturation of the Didemnin Anti-cancer Agents. J. Am. Chem. Soc. 2012, 134, 8625–8632. [Google Scholar] [CrossRef] [Green Version]
  18. Yu, Y.; van der Donk, W.A. Biosynthesis of 3–thia–α–amino acids on a carrier peptide. Proc. Natl. Acad. Sci. USA 2022, 119, e2205285119. [Google Scholar] [CrossRef]
  19. Lu, L.; Meehan, M.J.; Gu, S.; Chen, Z.; Zhang, W.; Zhang, G.; Liu, L.; Huang, X.; Dorrestein, P.C.; Xu, Y.; et al. Mechanism of Action of Thalassospiramides, A New Class of Calpain Inhibitors. Sci. Rep. 2015, 5, 8783. [Google Scholar] [CrossRef] [Green Version]
  20. Ross, A.C.; Xu, Y.; Lu, L.; Kersten, R.D.; Shao, Z.; Al-Suwailem, A.M.; Dorrestein, P.C.; Qian, P.-Y.; Moore, B.S. Biosynthetic Multitasking Facilitates Thalassospiramide Structural Diversity in Marine Bacteria. J. Am. Chem. Soc. 2013, 135, 1155–1162. [Google Scholar] [CrossRef]
  21. Duggan, B.M.; Cullum, R.; Fenical, W.; Amador, L.A.; Rodríguez, A.D.; La Clair, J.J. Searching for Small Molecules with an Atomic Sort. Angew. Chem. Int. Ed. 2020, 59, 1144–1148. [Google Scholar] [CrossRef] [PubMed]
  22. Schulze-Sünninghausen, D.; Becker, J.; Luy, B. Rapid Heteronuclear Single Quantum Correlation NMR Spectra at Natural Abundance. J. Am. Chem. Soc. 2014, 136, 1242–1245. [Google Scholar] [CrossRef] [PubMed]
  23. bcl2fastq: A Proprietary Illumina Software for the Conversion of bcl Files to Basecalls. Available online: https://support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversion-software.html (accessed on 11 January 2023).
  24. An Open Source Software for the QC and Adapter Trimming of ONT Technologies. Available online: https://github.com/rrwick/Porechop (accessed on 11 January 2023).
  25. Wick, R.R.; Judd, L.M.; Gorrie, C.L.; Holt, K.E. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol. 2017, 13, e1005595. [Google Scholar] [CrossRef] [PubMed]
Figure 2. 1H NMR spectra from a time course study on the growth of T. mobilis JCM21370. Didemnin B (1) could be detected in these cultures, as illustrated by comparing the NMR spectra of the extracts (black) to that of pure 1 (blue). Didemnin B (1) was isolated in a pure state after fractionation and chromatographic purification. Peaks from 1 (blue dots) are shown on each extract. NMR spectra of the 2 and cyclo(Pro–Tyr) (3) also isolated from T. mobilis JCM21370 are provided. Data from additional extracts (K-R, Table 2), including T. mobilis YIT12409, are provided within the Supplementary Information.
Figure 2. 1H NMR spectra from a time course study on the growth of T. mobilis JCM21370. Didemnin B (1) could be detected in these cultures, as illustrated by comparing the NMR spectra of the extracts (black) to that of pure 1 (blue). Didemnin B (1) was isolated in a pure state after fractionation and chromatographic purification. Peaks from 1 (blue dots) are shown on each extract. NMR spectra of the 2 and cyclo(Pro–Tyr) (3) also isolated from T. mobilis JCM21370 are provided. Data from additional extracts (K-R, Table 2), including T. mobilis YIT12409, are provided within the Supplementary Information.
Marinedrugs 21 00056 g002
Figure 3. Atomic Sort identification of didemnin B (1) in the T. mobilis JCM21370. Expansions of (a) the aromatic and (b) the methyl regions of the 1H–13C HSQC spectrum of the T. mobilis JCM21370 extract H (black) overlaid with spectra of didemnin B (1, red), cyclo(Pro–Tyr) (3, blue), Leu–Pro–Ile–Pro–Ile (2, green), and indole (magenta). All peaks of these metabolites are observed in the T. mobilis JCM21370 extract spectrum, along with additional weaker peaks from metabolites that were not identified. Extract H (Table 2) was used for this study.
Figure 3. Atomic Sort identification of didemnin B (1) in the T. mobilis JCM21370. Expansions of (a) the aromatic and (b) the methyl regions of the 1H–13C HSQC spectrum of the T. mobilis JCM21370 extract H (black) overlaid with spectra of didemnin B (1, red), cyclo(Pro–Tyr) (3, blue), Leu–Pro–Ile–Pro–Ile (2, green), and indole (magenta). All peaks of these metabolites are observed in the T. mobilis JCM21370 extract spectrum, along with additional weaker peaks from metabolites that were not identified. Extract H (Table 2) was used for this study.
Marinedrugs 21 00056 g003
Figure 4. Didemnin biosynthetic gene clusters (BGCs). (a) Structure of didemnin B (1) with the A domain amino acid loading (colored spheres) and positions of thioester coupling (hexagons). (b) Didemnin BGCs from three different strains of Tistrella. The BGCs identified in each strain contain unique combinations of didA–didJ with domain module contraction in T. mobilis JCM21370 when compared to that observed in T. mobilis KA081020–065 BGC [17]. The non-producing BGC in T. bauzanensis was truncated including only the first and last two genes. (c) Didemnin BGC identified from T. mobilis KA081020–065 with domain (spheres) and module (bar) architecture shown. One of the two TE domains was observed outside of the BGC (Orf4, not shown). The numbers within the hexagons indicate the positions of each ester linkage.
Figure 4. Didemnin biosynthetic gene clusters (BGCs). (a) Structure of didemnin B (1) with the A domain amino acid loading (colored spheres) and positions of thioester coupling (hexagons). (b) Didemnin BGCs from three different strains of Tistrella. The BGCs identified in each strain contain unique combinations of didA–didJ with domain module contraction in T. mobilis JCM21370 when compared to that observed in T. mobilis KA081020–065 BGC [17]. The non-producing BGC in T. bauzanensis was truncated including only the first and last two genes. (c) Didemnin BGC identified from T. mobilis KA081020–065 with domain (spheres) and module (bar) architecture shown. One of the two TE domains was observed outside of the BGC (Orf4, not shown). The numbers within the hexagons indicate the positions of each ester linkage.
Marinedrugs 21 00056 g004
Table 1. Antibiotic resistance screen a.
Table 1. Antibiotic resistance screen a.
Antibiotic (Concentration)T. mobilis
JCM21370
T. mobilis
YIT12409
apramycin (50 µg/mL)
carbenicillin (50 µg/mL)++++++
chloramphenicol (25 µg/mL)
colistin (5 µg/mL)+++
kanamycin (50 µg/mL)
hygromycin (100 µg/mL)
nalidixic acid (30 µg/mL)+
none++++++
a Growth given by − (none), + (slight), ++ (reduced), +++ (normal).
Table 2. Cultures evaluated in this study.
Table 2. Cultures evaluated in this study.
CultureStrain aMedia bV (mL)T (°C)Days
AJCM2137074NB200302
BJCM2137074NB5000303
CYIT1240974NB1000303
DYIT12409TSB1000303
EJCM2137074NB100303
FYIT1240974NB100303
GDSM2281774NB1003010
HJCM2137074NB2000303
IYIT1240974NB2000303
JDSM2281774NB2000206
KJCM2137074NB1000303
LYIT1240974NB1000303
MJCM2137074NB1000303
NJCM21370GYP1000303
OJCM21370SBM1000303
PYIT1240974NB1000303
QYIT12409GYP1000303
RYIT12409SBM1000303
SJCM21370GYP2000303
a Strains are listed by code number as given by JCM21370 for T. mobilis JCM21370, YIT12409 for T. mobilis YIT12409 and DSM22817 for T. bauzanensis DSM22817. b Media is given by 74NB for 74 Nutrient, TSB for Tryptic Soy Broth and GYP for glucose, yeast extract and peptone.
Table 3. Atomic Search Analyses of 1H–13C HSQC spectra from crude Tistrella extracts.
Table 3. Atomic Search Analyses of 1H–13C HSQC spectra from crude Tistrella extracts.
CompoundT. mobilis
JCM21370 (H a)
T. bauzanensis DSM22817 (I a)T. mobilis
YIT12409 (J a)
methanol0.009 b, 1/1 c0.001, 1/10.002, 1/1
indole0.032, 6/60.095, 6/60.058, 6/6
didemnin B (1)0.056, 51/510.587, 5/51 d0.389, 23/51
cyclo(Pro–Tyr) (3)0.063, 11/110.044, 11/110.142, 10/11
Leu–Pro–Ile–Pro–Ile (2)0.074, 27/270.054, 26/270.101, 23/27
cyclo(Ile–Pro–Leu–Pro)0.183, 19/260.175, 21/260.154, 17/26
n–hexane0.136, 2/30.123, 3/30.121, 2/3
a Letters denote the cultures described in Table 2. b The first number in each cell is the median Atomic Sort distance ( d A S ˜ ). c The numerator of the fraction is the number of peaks that matched with dAS ≤ 0.25. The denominator is the total number of peaks for that compound. d The didemnin B d A S ˜ and match fraction for the T. bauzanensis DSM22817 strain is included for comparison. The values indicate the match was poor and that 1 was not present.
Table 4. Yields of the identified compounds in extract of Tistrella cultures.
Table 4. Yields of the identified compounds in extract of Tistrella cultures.
Database Hit
Compound
T. mobilis
JCM21370 (H a)
T. bauzanensis DSM22817 (I a)T. mobilis
YIT12409 (J a)
[] b, mMYield c, µg[] b, mMYield c, µg[] b, mMYield c, µg
indole51.2300.79.053.1135.4795.5
didemnin B (1)7.7427.51.8102.7
cyclo(Pro–Tyr) (3)22.6294.225.6333.222.7295.9
Leu–Pro–Ile–Pro–Ile (2)17.5483.518.4507.516.3449.9
cyclo(Ile–Pro–Leu–Pro)30.6643.925.7540.228.0588.9
a Letters denote the cultures described in Table 2. b Concentrations of each compound in the NMR sample. These values represent an estimated concentration based on NMR integration within the 1H NMR spectrum of each sample and do not reflect isolated yields. c The mass calculations assumed an NMR volume of 50 µL, Leu-Pro-Ile-Pro-Ile (2) was the linear pentapeptide with MW = 551.72, and cyclo(Ile–Pro–Leu–Pro) had MW = 420.6. Care was taken to load 50 ± 2 µL into each NMR tube.
Table 5. Yields of didemnin B (1) in extracts of T. mobilis strains JCM21370 and YIT12409 cultures.
Table 5. Yields of didemnin B (1) in extracts of T. mobilis strains JCM21370 and YIT12409 cultures.
MediaT. mobilis JCM21370T. mobilis YIT12409
Culture a[] b, mMYield c, µgTiter d, mg/LCulture a[] b, mMYield c, µgTiter d, mg/L
74NBK7.1397.354.8L4.4247.434.1
74NBM14.6809.9111.7P4.7258.835.7
GYPN3.7203.528.2Q6.8375.851.8
SBMO7.1393.054.2R5.7319.044.0
a Letters denote the cultures described in Table 2. b Concentrations of each compound in the NMR sample. These values represent an estimated concentration based on NMR integration within the 1H NMR spectrum of each sample and do not reflect isolated yields. c The mass calculations assumed a volume of 50 µL within the NMR sample. Care was taken to load 50 ± 2 µL into each NMR tube. d All cultures were conducted at 1 L scale with 2% m/m of the crude extract used for NMR analyses.
Table 6. Tabulated NMR data from didemnin B (1) in CD3OD a,b.
Table 6. Tabulated NMR data from didemnin B (1) in CD3OD a,b.
Positionδ 1H, Mult (J in Hz)δ13C1H, 1H–COSY1H, 13C–HMBC
Ist1172.9
Ist2a3.61, m40.3Ist2bIst1
Ist2b2.43, dd (10.4, 17.5)Ist2a, Ist3Ist1, Ist3
Ist34.05, t (10.5)67.6Ist2bIst1, Ist4
Ist43.97, td (10.3, 2.5)56.6IstNH, Ist5Ist3, Ist6
Ist52.00, m34.9Ist4, Ist6Ist7w
Ist60.98, d (7.2)14.5Ist5, Ist7a, Ist7bIst4, Ist7
Ist7a1.40, m Ist5, Ist6, Ist7b, Ist8Ist4w, Ist5w Ist6w, Ist8w
Ist7b1.26, m Ist5, Ist6, Ist7a, Ist8Ist4w, Ist5w, Ist6w, Ist8w
Ist80.97, d (6.6)12.1Ist7
IstNH7.35, d (10.0)Ist4Thr1w
Hip1171.3
Hip24.12, q (6.7)49.2Hip3Hip1, Hip3, Hip4
Hip31.30, d (6.9)15.9Hip2Hip1, Hip2, Hip4
Hip4205.7
Hip55.05, d (4.0)81.9Hip6Hip4, Hip6, Hip7, Hip8w, Ist1
Hip62.32, m31.0Hip5, Hip7, Hip8Hip8w
Hip70.87, d (6.9)17.0Hip6Hip5, Hip6, Hip8
Hip80.93, d (6.8)19.2Hip6Hip5, Hip6, Hip7
Leu1171.5
Leu24.78, m50.6LeuNH, Leu3a, Leu3b
Leu3a1.64, m42.2Leu2, Leu3b
Leu3b1.23, mLeu2, Leu3a
Leu41.52, m25.7Leu3a, Leu3b, Leu5, Leu6
Leu50.92, d (6.7)21.2Leu4Leu3, Leu4, Leu6
Leu60.96, d (6.9)23.8Leu4Leu3, Leu4, Leu5
LeuNH8.1, d (9.2)Leu2Hip1
Pro1172.5
Pro24.80, m58.4Pro3a, Pro3b
Pro3a2.19, m28.7Pro2, Pro3bPro1, Pro2w
Pro3b1.70, dt (12.3, 6.1)Pro2, Pro3aPro1, Pro5
Pro42.06, m25.5Pro5a, Pro5bPro2, Pro5
Pro5a3.74, dt (9.7, 6.8)47.9Pro4
Pro5b3.58, dt (5.3, 3.1)Pro4Pro1
MTyr1170.0
MTyr24.01. dd (10.6, 4.7)66.3MTyr3a, MTyr3bMTyr1, MTyr3, MTyrNM, Pro1
MTyr3a3.15, dd (14.1, 10.7)34.6MTyr2, MTyr3bMTyr1w, MTyr2, MTyr4, MTyr5
MTyr3b3.29, mMTyr2, MTyr3aMTyr2, MTyr4, MTyr5
MTyr4130.6
MTyr57.14, d (8.6)131.8MTyr6MTyr3, MTyr5, MTyr6, MTyr7
MTyr66.88, d (8.5)114.7MTyr5MTry4, MTyr6, MTyr7
MTyr7159.8
MTyr83.78, s55.3 MTyr7
MTyrNMe2.62, s39.1
Thr1171.1
Thr24.54, dd (5.1, 2.4)59.1ThrNHThr3, Thr4w
Thr35.37, d (5.9)71.1Thr4Thr2w, MTyr1
Thr41.35, d (6.3)16.6Thr3Thr2, Thr3
ThrNH7.94, d (4.9)Thr2MLeu1
MLeu1173.0
MLeu25.39, d (8.2)55.9MLeu3HPro1, MLeu1, MLeu3, MeLeu4, MLeuNMe
MLeu31.80, dd (8.5, 6.9)37.0MLeu2, MLeu4HPro1, MLeu1, MLeu2, MLeu4, MLeu5, MLeu6
MLeu41.47, m25.5MLeu3, MLeu5, MLeu6MLeu3, MLeu4, MLeu5
MLeu50.89, d (6.5)21.3MLeu4MLeu3, MLeu4, MLeu6
MLeu60.95, d (6.7)23.8MLeu4MLeu3, MLeu4, MLeu5
MLeuNMe3.19, s31.5MLeu2, HPro1
HPro1175.4
HPro24.84, m58.0HPro3a, HPro3bHPro3
HPro3a2.28, m29.2HPro2, HPro3bHPro5w
HPro3b1.85, mHPro2, HPro3aHPro1w
HPro4a2.16, m26.6HPro4b, HPro5a, HPro5b
HPro4b2.03, mHPro4a, HPro5a, HPro5bHPro2, HPro3, HPro5
HPro5a3.88, ddd (10.8, 7.3, 3.6)48.1HPro4a, HPro4b, HPro5bHPro4w
HPro5b3.64, dd (10.0, 6.6)HPro4a, HPro4b, HPro5a
HP1174.1
HP24.47, q (6.6)67.3HP3HP1, HP3
HP31.38, d (6.6)19.9HP2HP1, HP2
a Abbreviations: MTyr = N–methylTyr, MLeu = N–methylLeu, SHP = N–(S)–2–hydroxypropanoyl. b Coupling abbreviations are given by s = singlet, d = doublet, t = triplet, q = quartet and m = multiplet.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Stankey, R.J.; Johnson, D.; Duggan, B.M.; Mead, D.A.; La Clair, J.J. A Survey of Didemnin Depsipeptide Production in Tistrella. Mar. Drugs 2023, 21, 56. https://doi.org/10.3390/md21020056

AMA Style

Stankey RJ, Johnson D, Duggan BM, Mead DA, La Clair JJ. A Survey of Didemnin Depsipeptide Production in Tistrella. Marine Drugs. 2023; 21(2):56. https://doi.org/10.3390/md21020056

Chicago/Turabian Style

Stankey, Robert J., Don Johnson, Brendan M. Duggan, David A. Mead, and James J. La Clair. 2023. "A Survey of Didemnin Depsipeptide Production in Tistrella" Marine Drugs 21, no. 2: 56. https://doi.org/10.3390/md21020056

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop